23 June 2021 | News
In February this year, BIOKANGTAI and Malaysia's Yong Tai Berhad signed an Agreement on Phase III Clinical Trial of Inactivated COVID-19 Vaccine
Image credit- shutterstock.com
Phase III clinical fieldwork of the Inactivated COVID-19 Vaccine (Vero cells) independently developed and manufactured by Shenzhen Kangtai Biological Products Co., Ltd. has been officially initiated in Malaysia, and the first batch of enrolled subjects was vaccinated on-site on June 21st.
In February this year, BIOKANGTAI and Malaysia's Yong Tai Berhad signed an Agreement on Phase III Clinical Trial of Inactivated COVID-19 Vaccine and Product Procurement, reaching a consensus to further carry out the phase III clinical trials and commercialization of the agreed products in Malaysia.
On May 31, the National Pharmaceutical Regulatory Agency (NPRA), Malaysia, approved the clinical trial of the vaccine. Subsequently, on June 11, clinical samples of the vaccine were delivered from Shenzhen, China to Malaysia.
Regarding this collaborative clinical trial, Miao Xiang, executive vice chairman of BIOKANGTAI, said, "In the face of the pandemic, BIOKANGTAI, together with our Malaysian partner, will provide Malaysians with COVID-19 vaccines which have been proven to be safe on a large scale, to help Malaysia overcome the epidemic as soon as possible with our responsibility and duty as a Chinese vaccine enterprise. At the same time, both companies will actively promote the roll-out of the phase III clinical trial, to accelerate the fair supply of COVID-19 vaccines as a public product in the world, especially in developing countries, by verifying the effectiveness and safety of the vaccine on a larger scale."
Datuk Wira Boo Kuang Loon, CEO of Yong Tai Berhad said, " The COVID-19 Vaccine will become a long-term demand, and we currently lack the technology to produce vaccines on our own, we hope to introduce the advanced technology of BIOKANGTAI and to promote local R&D and manufacturing."